Nuvalent

Nuvalent, Inc. operates as a preclinical stage biopharmaceutical company. The company creates precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Its focus its discovery efforts on small molecule inhibitors of kinases, a class of cellular targets that can play a central role in cancer growth and proliferation. The company was founded in January 2017 and is headquartered Cambridge, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nuvalent, Inc. is a clinical stage biopharmaceutical company, which focuses on creating precisely targeted therapies for patients with cancer. Its pipeline includes ROS1 NSCLC, ALK NSCLC and HER2 NSCLC. The company was founded by Matthew D. Shair in January 2017 and is headquartered in Cambridge, MA.

Chesapeake Energy

Traeger

Candel Therapeutics

Rallybio Corp

Riskified Ltd

With the trading day more than halfway over, the broad markets had a roaring start to the week with the S&P 500 and Nasdaq hitting record intraday highs.

Monday Afternoon Analyst Upgrades and Downgrades: Chesapeake Energy, Traeger and More

CAMBRIDGE, Mass., Aug. 2, 2021 /PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the closing of its upsized initial public offering of 11,212,500 shares of common stock, consisting of 10,612,500 shares of Class A common stock and 600,000 shares of Class B common stock, which includes 1,462,500 shares of Class A common stock sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, each at a price to the public of $17.00 per share.

Nuvalent Announces Closing of Upsized Initial Public Offering

Robinhood

Icosavax

Making their market debuts were three biotechs, a fintech, and a grill maker. Shares of one biotech, Icosavax, rocketed 214%.

5 Companies Join Robinhood in Going Public

Nuvalent has filed proposed terms for a $151 million IPO.

Nuvalent Finalizes $151 Million IPO Plan

CAMBRIDGE, Mass., July 28, 2021 /PRNewswire/ -- Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of its initial public offering of 9,750,000 shares of common stock, consisting of 9,150,000 shares of Class A common stock and 600,000 shares of Class B common stock, each at a price to the public of $17.00 per share.

Nuvalent Announces Pricing of Initial Public Offering

Nuvalent is advancing drug candidates with structure-based design to inhibit kinase targets in oncologic diseases. The candidates are developed to prioritize kinase selectivity while minimizing adverse events and driving durable responses.

Nuvalent: Structure-Based Drugs To Inhibit Kinase Targets

News for Nuvalent Stock (NUVL)